Vanda Pharmaceuticals (VNDA)

Vanda’s commercial portfolio includes Fanapt, an antipsychotic approved for the treatment of schizophrenia, and Hetlioz, a therapy associated with circadian rhythm-related sleep disorders, including Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis syndrome. The company also has rights to Ponvory in certain contexts and continues to evaluate additional therapeutic candidates, including assets such as tradipitant, VQW-765, VTR-297, and antisense oligonucleotide programmes.

The company generates revenue primarily from sales of approved medicines, with the United States representing its main commercial market. It also has activity in selected international markets, including parts of Europe, Canada, and Israel. Like many specialty pharmaceutical businesses, Vanda’s performance depends on prescription demand, payer coverage, regulatory decisions, intellectual property protection, and the ability to advance pipeline candidates through clinical trials.

Vanda is distinctive for its emphasis on disorders that are often complex, underdiagnosed, or underserved by existing therapies. Its work in circadian biology, neuropsychiatry, gastrointestinal-related indications, and precision-style drug development reflects a strategy of targeting areas where differentiated medicines may command clinical and commercial value. For investors, the stock represents exposure to a small-to-mid-sized pharmaceutical company with established products, ongoing research programmes, and the risks typical of drug development and specialty medicine commercialisation.